Background: The present study performs to improve the medicinal properties of Syzygium Aromaticum L by processing S. Aromaticum L. Bud essential oil (SABE) to the Nano Emulsion drug delivery system (SABE-NE) and investigate its anti-tumor and apoptotic impacts on human HT-29 colon cancer cells and to evaluate the toxicity of SABE-NE. Applying the ultra-sonication method and characterization by DLS and FESEM analysis facilitates the nano-emulsification procedure. Then both human cancer (HT-29) and normal (HFF) cell lines were evaluated based on the SABE-NE apoptotic and cytotoxic impacts. In an in-vitro section, flow cytometry method, Cas3 gene profile, AO/PI cell staining, and MTT assays apply to analyze the apoptotic and cytotoxic activities, and in further analysis measuring liver lipid peroxidation and antioxidant genes expression (SOD, CAT, and GPx) investigate in mice organs alterations. Result: As a result, produced 131.2 nm SABE-NE induces apoptosis response and cellular death (Cas3 up-regulation and enhanced SubG1 peaks), and subsequently, the HT-29 cells' viability can reduce significantly, while HFF cells indicate confined cytotoxic impacts. Moreover, in-vivo test results on mice liver demonstrate the cytoprotective properties of SABE-NE (reduced lipid peroxidation and increased antioxidant enzymes gene expression and non-detectable cytotoxic impacts).Conclusion: We produced a novel nature nanoemulsion drug delivery system called SABE-NE, which is cell-specific apoptotic inducer and thus can be utilized as an efficient anti-cancer compound for human colon cancer treatment. However, to verify and approve its cell-specific anti-tumor activity, further supplementary studies are required.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.